Prostate Cancer Treatment Market Report by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies), and Region 2024-2032
전 세계 전립선암 치료 시장 규모는 2023년 77억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 사이 5.1%의 연평균 성장률(CAGR)을 보이며 2032년까지 121억 달러에 달할 것으로 예측했습니다.
전립선암은 심각한 악성 종양의 일종으로, 남성의 전립선에 존재하는 다양한 비정상 세포의 통제할 수 없는 분열과 확대로 인해 발생합니다. 백신, 약물요법, 치료법 등 다양한 치료법을 통해 치료할 수 있습니다. 그 중 화학요법, 면역요법, 냉동요법, 수술요법, 호르몬요법, 표적요법, 방사선요법 등은 체내 암세포의 확산을 억제하는 데 도움이 되는 가장 보편적인 치료법입니다. 이러한 치료법은 환자의 나이, 증상의 심각성, 병력, 과거 병력 등 다양한 평가에 따라 환자에게 제공됩니다.
전립선암 치료 시장 동향:
전립선암 유병률의 증가, 특히 노인 인구의 증가는 현재 전립선암 시장을 성장시키는 주요 요인 중 하나입니다. 이와 함께 환자 지원 프로그램(PAP)을 도입하기 위해 여러 국가의 정부 기관에서 시행하고 있는 여러 가지 노력과 유리한 의료비 상환 정책의 가용성은 다른 성장 촉진요인으로 작용하고 있습니다. PAP는 제약회사가 관리하는 조직적인 프로그램으로, 치료 목적의 의약품을 무료로 제공함으로써 환자에게 경제적 지원을 명시하고 있습니다. 또한, 다중 파라미터 자기공명영상(mp-MRI) 장비와 비전이성 거세 저항성 전립선암(nmCRPC) 및 전이성 호르몬 전이성 전립선암(mHNPC) 설정과의 통합과 같은 전립선암을 조기에 발견하고 진단 오류를 줄이기 위한 기술 발전도 시장 성장에 기여하고 있습니다. 또한, 새로운 치료 제품을 도입하기 위한 연구 개발(R&D) 활동에 대한 광범위한 투자와 다양한 온라인 및 오프라인 유통 채널에서 쉽게 구할 수 있다는 점도 시장 전망을 밝게 하고 있습니다.
본 보고서에서 다루는 주요 질문들
- 2023년 세계 전립선암 치료 시장 규모는?
- 2024-2032년 세계 전립선암 치료 시장 성장률 전망은?
- 전립선암 치료 세계 시장을 이끄는 주요 요인은 무엇인가?
- COVID-19가 전립선암 치료 세계 시장에 미치는 영향은?
- 전세계 전립선암 치료 시장에서 약제 유형별 분류는?
- 유통 채널별 전립선암 치료 세계 시장 현황은?
- 전세계 전립선암 치료 시장의 주요 지역은?
- 전세계 전립선암 치료 시장에 진출한 주요 업체는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 전립선암 치료 세계 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 약제 유형별
제7장 시장 내역 : 유통 채널별
- 병원 약국
- 드럭스토어 및 소매 약국
- 온라인 약국
제8장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Astellas Pharma Inc.
- AstraZeneca plc
- Bayer Aktiengesellschaft
- Dendreon Pharmaceuticals LLC.(Sanpower Group Co. Ltd.)
- F. Hoffmann-La Roche AG
- Ferring B.V.
- GlaxoSmithKline Plc
- Ipsen(Mayroy SA)
- Novartis International AG
- Takeda Pharmaceutical Company Ltd.
- Tolmar Pharmaceuticals Inc.
ksm
The global prostate cancer treatment market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Prostate cancer is a type of severe malignant tumor, which is caused by the uncontrollable division and expansion of various abnormal cells in the prostate gland present in men. It can be treated through the use of various therapeutics, such as vaccines, medications, and treatments. Amongst these, chemotherapy, immunotherapy, cryotherapy, surgery, hormonal, targeted and radiation therapy are some of the most common treatment types that aid in mitigating the spread of cancer cells in the body. These therapies are provided to the patient based on various assessments, such as the age of the patient, severity of the symptoms experienced, medical condition, and previous health history.
Prostate Cancer Treatment Market Trends:
The increasing prevalence of prostate cancer, especially amongst the rising geriatric population, is one of the prime factors currently driving the market toward growth. In line with this, the availability of favorable medical reimbursement policies and the numerous initiatives being undertaken by the government bodies of several countries for introducing patient assistance programs (PAPs) are acting as other growth-inducing factors. PAP is an organized program, which is controlled by pharmaceutical companies for providing financial assistance to patients by offering free medications for treatment purposes. Moreover, significant technological advancements, such as the integration of multiparametric-magnetic resonance imaging (mp-MRI) devices with non-metastatic castration-resistant (nmCRPC) and metastatic hormone nave (mHNPC) settings for detecting prostate cancer at early stages, while mitigating diagnostic errors, is also contributing to the market growth. Additionally, extensive investments in the research and development (R&D) activities to introduce novel therapeutic products, along with their easy availability across various online and offline distribution channels, are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global prostate cancer treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug type and distribution channel.
Breakup by Drug Type:
Chemotherapy
Biological Therapy
Hormone Therapy
Others
Breakup by Distribution Channel:
Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., AstraZeneca plc, Bayer Aktiengesellschaft, Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.), F. Hoffmann-La Roche AG, Ferring B.V., GlaxoSmithKline Plc, Ipsen (Mayroy SA), Novartis International AG, Takeda Pharmaceutical Company Ltd. and Tolmar Pharmaceuticals Inc.
Key Questions Answered in This Report
- 1. What was the size of the global prostate cancer treatment market in 2023?
- 2. What is the expected growth rate of the global prostate cancer treatment market during 2024-2032?
- 3. What are the key factors driving the global prostate cancer treatment market?
- 4. What has been the impact of COVID-19 on the global prostate cancer treatment market?
- 5. What is the breakup of the global prostate cancer treatment market based on drug type?
- 6. What is the breakup of the global prostate cancer treatment market based on the distribution channel?
- 7. What are the key regions in the global prostate cancer treatment market?
- 8. Who are the key players/companies in the global prostate cancer treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Prostate Cancer Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Type
- 6.1 Chemotherapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Biological Therapy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Hormone Therapy
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Distribution Channel
- 7.1 Hospitals Pharmacies
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Drug Stores and Retail Pharmacies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Online Pharmacies
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Astellas Pharma Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 AstraZeneca plc
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Bayer Aktiengesellschaft
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.)
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.5 F. Hoffmann-La Roche AG
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.6 Ferring B.V.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 GlaxoSmithKline Plc
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Ipsen (Mayroy SA)
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.9 Novartis International AG
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Takeda Pharmaceutical Company Ltd.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.10.3 Financials
- 13.3.10.4 SWOT Analysis
- 13.3.11 Tolmar Pharmaceuticals Inc.
- 13.3.11.1 Company Overview
- 13.3.11.2 Product Portfolio
